Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials

Van Thu Nguyen*, Philippe Rivière, Pierre Ripoll, Julien Barnier, Romain Vuillemot, Gabriel Ferrand, Sarah Cohen-Boulakia, Philippe Ravaud, Isabelle Boutron, The COVID-NMA Consortium Team, Alice Fabri (Medlem af forfattergruppering), Camilla Hansen (Medlem af forfattergruppering), Asbjørn Hróbjartsson (Medlem af forfattergruppering)

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

12 Downloads (Pure)


Objectives: Researchers worldwide are actively engaging in research activities to search for preventive and therapeutic interventions against coronavirus disease 2019 (COVID-19). Our aim was to describe the planning of randomized controlled trials (RCTs) in terms of timing related to the course of the COVID-19 epidemic and research question evaluated. Study Design and Setting: We performed a living mapping of RCTs registered in the WHO International Clinical Trials Registry Platform. We systematically search the platform every week for all RCTs evaluating preventive interventions and treatments for COVID-19 and created a publicly available interactive mapping tool at to visualize all trials registered. Results: By August 12, 2020, 1,568 trials for COVID-19 were registered worldwide. Overall, the median ([Q1–Q3]; range) delay between the first case recorded in each country and the first RCT registered was 47 days ([33–67]; 15–163). For the 9 countries with the highest number of trials registered, most trials were registered after the peak of the epidemic (from 100% trials in Italy to 38% in the United States). Most trials evaluated treatments (1,333 trials; 85%); only 223 (14%) evaluated preventive strategies and 12 postacute period intervention. A total of 254 trials were planned to assess different regimens of hydroxychloroquine with an expected sample size of 110,883 patients. Conclusion: This living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in research questions. Most trials were registered when the first peak of the pandemic has passed.

TidsskriftJournal of Clinical Epidemiology
Sider (fra-til)107-116
StatusUdgivet - feb. 2021

Bibliografisk note

Funding Information:
Funding: This study received funding from the Agence Nationale de la Recherche (ANR), France. The funder had no role in the design, analysis, and reporting of this study.

Publisher Copyright:
© 2020 The Author(s)

Copyright 2020 Elsevier B.V., All rights reserved.

Fingeraftryk Dyk ned i forskningsemnerne om 'Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials'. Sammen danner de et unikt fingeraftryk.